Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

296 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphoma.
Nastoupil LJ, Neelapu SS, Davis RE, Samaniego F, Fowler NH, Westin J, Lee HJ, Wang M, Hagemeister F, Cecil ARL, Dow J, Haque K, Silva FA, Whale A, Lensun L, Bone EA, McElwaine-Johnn H, Beer PA. Nastoupil LJ, et al. Among authors: neelapu ss. Leuk Lymphoma. 2021 Dec;62(14):3452-3462. doi: 10.1080/10428194.2021.1957874. Epub 2021 Aug 9. Leuk Lymphoma. 2021. PMID: 34365878 Clinical Trial.
Phase III randomized trial of patient-specific vaccination for previously untreated patients with follicular lymphoma in first complete remission: protocol summary and interim report.
Neelapu SS, Gause BL, Nikcevich DA, Schuster SJ, Winter J, Gockerman JP, Loughran T Jr, Takeshita K, Inghirami G, McGaughey D, Watson TM, Snow S, Kubovic P, Ferraro M, Jones E, Jaffe ES, Schwartzentruber DJ, Danforth D, Sherry R, Kass E, Van Waes C, Reynolds CW, Kwak LJ. Neelapu SS, et al. Clin Lymphoma. 2005 Jun;6(1):61-4. doi: 10.3816/clm.2005.n.031. Clin Lymphoma. 2005. PMID: 15989711 Clinical Trial. No abstract available.
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.
Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, Medeiros LJ, Fayad L, Samaniego F, Alousi A, Anderlini P, Couriel D, de Lima M, Giralt S, Neelapu SS, Ueno NT, Samuels BI, Hagemeister F, Kwak LW, Champlin RE. Khouri IF, et al. Among authors: neelapu ss. Blood. 2008 Jun 15;111(12):5530-6. doi: 10.1182/blood-2008-01-136242. Epub 2008 Apr 14. Blood. 2008. PMID: 18411419 Free PMC article. Clinical Trial.
Vaccination strategies in follicular lymphoma.
Kannan S, Neelapu SS. Kannan S, et al. Among authors: neelapu ss. Curr Hematol Malig Rep. 2009 Oct;4(4):189-95. doi: 10.1007/s11899-009-0025-2. Curr Hematol Malig Rep. 2009. PMID: 20425407 Review.
Prospective isolation of clonogenic mantle cell lymphoma-initiating cells.
Chen Z, Ayala P, Wang M, Fayad L, Katz RL, Romaguera J, Caraway N, Neelapu SS, Kwak LW, Simmons PJ, McCarty N. Chen Z, et al. Among authors: neelapu ss. Stem Cell Res. 2010 Nov;5(3):212-25. doi: 10.1016/j.scr.2010.07.003. Epub 2010 Aug 6. Stem Cell Res. 2010. PMID: 20851072 Free PMC article.
296 results